

melanoma and other skin tumours

1124P TREATMENT PATTERNS AND DISEASE BURDEN OF STAGE IIIB/IIIC MELANOMA IN FRANCE, GERMANY AND THE UK

P. Mohr¹, M. Harries², F. Grange³, R. Ehness⁴, L. Benjamin⁵, O. Siakpere⁶, L. McLeod⁷, S. Wolowacz⁸, J.A. Kaye⁹, I. Kontoudis¹⁰

¹Clinic of Dermatology, Dermatologic Center Buxtehude, Buxtehude, GERMANY

²Department of Medical Oncology, Guys and St Thomas's Hospitals NHS Foundation Trust, Guys Hospital, London, UK

³Dermatology, Reims University Hospital, Reims, FRANCE

⁴Medical Hematology/oncology, GlaxoSmithKline GmbH & Co KG, Munich, GERMANY

⁵Health Economics and Outcomes Research, GlaxoSmithKline France, Marly le Roi, FRANCE

⁶Medical, GlaxoSmithKline UK, Middlesex, UK

⁷Patient-reported Outcomes, RTI Health Solutions, Research Triangle Park, NC, USA

⁸Health Economics, RTI Health Solutions, Manchester, UK

⁹Epidemiology, RTI Health Solutions, Waltham, MA, USA

¹⁰ITX, GlaxoSmithKline Vaccines, Rixensart, BELGIUM

Aim: Real-world data on treatment patterns and costs are often scarce, although much needed for health technology assessments governing patient access in many countries. This study aimed to collect these data in France, Germany and the UK for patients with stage IIIB/IIIC melanoma with macroscopic lymph node involvement, whose primary melanoma and regional lymph node metastases had been completely resected.

Methods: This retrospective observational study enrolled patients aged ≥ 18 years first diagnosed between 1 January 2009 and 31 December 2011. Data were extracted from patients' medical records until death or study end date, and via a patient survey. Costs were calculated by collecting resource use and multiplying by unit costs.

Results: 49 centres provided data on 558 patients. Overall, 56% of patients were male and 58% were aged <65 years at diagnosis. Over half had stage IIIB disease. The mean total direct cost per patient over the entire medical record follow-up period was €23,582 in France, €32,058 in Germany, and £31,123 (€35,791) in the UK. The table shows the use of adjuvant systemic therapies in each country.

Table: 1124P Adjuvant systemic therapy received, n (%)

	France	Germany	UK
None	185 (93.0)	109 (66.5)	190 (97.4)
Interferon			
High dose	3 (1.5)	18 (11.0)	0
intermediate dose	1 (0.5)	8 (4.9)	0
low dose	0	25 (15.2)	0
pegylated	0	3 (1.8)	0
Other	10 (5.0)	1 (0.6)	5 (2.6)
Total	199	164	195

Conclusions: Although the great majority of patients received no adjuvant treatment in France (93%) and the UK (97.4%), there was some use of interferon in Germany (high dose 11%; intermediate dose 5%; low dose 15%; pegylated 2%). Relatively high direct costs were observed in all three countries.

Disclosure: P. Mohr: PM received consulting fees and honoraria fees from GlaxoSmithKline group of companies, Roche, Merck, SciBase, Bristol-Myers Squibb, Novartis and Leo. He also received research funding from Merck; M. Harries: MH has received honoraria from GlaxoSmithKline group of companies for advisory boards; F. Grange: FG acted as an investigator in GlaxoSmithKline group of companies' studies and as a scientific advisor for GlaxoSmithKline group of companies; R. Ehness: RE is an employee of the GlaxoSmithKline group of companies and holds stock or stock options or restricted shares in GlaxoSmithKline group of companies; L. Benjamin: LB is an employee of the GlaxoSmithKline group of companies and holds stock or stock options or restricted shares in GlaxoSmithKline group of companies; O. Siakpere: OS is an employee of the GlaxoSmithKline group of companies and holds stock or stock options or restricted shares in GlaxoSmithKline group of companies; L. McLeod: LM is full-time employees of RTI Health Solutions, which received funding from GlaxoSmithKline group of companies to conduct this study; S. Wolowacz: SW is full-time employees of RTI Health Solutions, which received funding from GlaxoSmithKline group of companies to conduct this study; J.A. Kaye: JAK is full-time employees of RTI Health Solutions, which received funding from GlaxoSmithKline group of companies to conduct this study. I. Kontoudis: IK is an employee of the GlaxoSmithKline group of companies.